1. Luksameesate P, Nerapusee O, Patikorn C, Anantachoti P. Scoping review of international experience of a dedicated fund to support patient access to cancer drugs: policy implications for Thailand. Int J Health Policy Manag. 2024;13:7768. doi:10.34172/ijhpm.2023.7768
2. Lee JH. Establishing a dedicated fund to improve patient access to cancer medicines: key considerations and policy implications for Thailand: Comment on “Scoping review of international experience of a dedicated fund to support patient access to cancer drugs: policy implications for Thailand.” Int J Health Policy Manag. 2025;14:9153. doi:10.34172/ijhpm.9153
3. Sakulbumrungsil R, Kessomboon N, Kanchanapibool I, et al. The impact of drug financing system under Thailand universal health coverage (UHC) on the performances of drug system. Journal of Health Science of Thailand. 2020;29:S59-S71.
4. Patikorn C, Taychakhoonavudh S, Thathong T, Anantachoti P. Patient access to anti-cancer medicines under public health insurance schemes in Thailand: A mixed methods study. Thai Journal of Pharmaceutical Sciences. 2019;43(3):168-178.
5. Taychakhoonavudh S, Phoolcharoen W, Pesirikan N, et al. The landscape of biologics drug system in Thailand. Journal of Health Science of Thailand. 2020;29:S96-S111.
6. Kaso AW, Regesu AH, Haftu HK, et al. Magnitude of catastrophic health expenditure and its determinants among cancer patients in low and middle-income countries: a systematic review and meta-analysis. BMC Health Serv Res. 2025;25(1):1533. doi:10.1186/s12913-025-13723-4
7. Ungtrakul T, Siripaibun J, Anantachoti P, et al. Exploring alternative funding mechanisms to improve patient access to innovative medicines. BMC Health Services Research. 2026;26(1):644. doi:10.1186/s12913-026-14438-w
8. Chulalongkorn University, Chulabhorn Royal Academy. Feasibility of Implementing Cancer Drugs Fund in Thailand. https://online.pubhtml5.com/vyjq/hvdv/. Accessed June 15, 2026. Published 2025.
